February 11, 2014 - ACT was granted U.S. Patent 8,648,051 B2 “Antiproliferative Activity of G-Rich Oligonucleotides and Methods of the Using Same to Bind Nucleoin”


October 29, 2013 - ACT moved into The Nucleus facility located at 300 East Market Street, Louisville, KY 40202


October 15, 2013 - U.S. Patent 8,557,823 B2 'Family of PFKFB3 Inhibitors with Antineoplastic Properties' granted


April 12, 2013 - U.S. Granted Patent 8,410,070 B2 for PU27


December 22, 2012 - ACT awarded Federal and State SBIR awards totaling over $300,000

November 28, 2012 - ACT electronically submits IND Application for PFKFB3


October 9, 2012 - U.S. Granted Patent 8,283,332 B2 for PFKFB3


February 14, 2012 - U.S. Granted Patent 8,114,850 B2 for GRO-777




noteworthy 


Dr. Jason Chesney was invited to speak at the Targeted Anticancer Therapies (TAT) Conference being held in Washington, D.C. March 21-23, 2016.   Dr. Chesney's presentation on PFK-158. The presentation is titled “Phase I Trial of a First-In-Class PFKFB3 Inhibitor Reveals a Novel Immunostimulatory Mechanism of Action.”

Dr. Tapolsky, on behalf of ACT, submitted an abstract for the Annual American Association for Cancer Research (AACR) meeting held April 16-20, 2016 in New Orleans.

Dr. Tapolsky submitted an abstract to an AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care. That conference was held May 12-15, 2016 in Orlando.

Dr. Tapolsky also submitted an abstract to the American Society of Clinical Oncology (ASCO) held June 3-7, 2016 in Chicago. The topic of the abstract is PFK-158.


​Randall Riggs attended and had several one-on-one meetings with potential partners for PFK158 at key conferences such as JP Morgan Healthcare Conference and the Biotech Showcase in San Francisco in January. Mr. Riggs also attended and held several meetings with pharmaceutical companies at the BIO International Convention June 14-18, 2015 in Philadelphia.

ACT/Dr. Gilles Tapolsky was invited to present at an international scientific conference, the American Associate for Cancer Research (AACR), April 17-22, 2015 in Philadelphia. He provided an update/presentation on ACT’s First-in-Man, First-in-Class Phase I anti-cancer drug referred to as PFK158.

ACT was also invited to present at the American Society of Clinical Oncology (ASCO), May 29-June 2, 2015 in Chicago. Dr. Tapolsky provided an update/presentation on ACT’s First-in-Man Phase I anti-cancer drug.

​ACT was awarded #3 in The University of Houston's 2014 Cougar 100 companies! Click HERE to read more.


Dr. Tapolsky made a presentation "Characterization of PFKFB3 Inhibitor Entering the Clinic" at the 2nd Annual Cancer Metabolism Conference, October 9-10, 2014 in Boston.


ACT presented a poster during the 2014 AACR Annual meeting, titled “Grich DNA Genomic Sequences Derived from the Promoter Region of ProOncogenes Inhibit Tumor Growth and Demonstrate Synergies”, that highlighted the preclinical properties of oligonucleotides inhibiting cMyc, Bcl2, and Kras.

Dr. Jason Chesney, Deputy Director, Brown Cancer Center, was invited to make an oral presentation at the 2014 AACR annual meeting on PFK158. The presentation, titled “Identification of a PFKFB3 inhibitor suitable for phase I trial testing that synergizes with the BRaf inhibitor vemurafenib” highlighted the preclinical characteristics of PFK158 and described its synergy with BRAF inhibitors

Advanced Cancer Therapeutics